» Articles » PMID: 37805585

Stabilizing Histamine Release in Gut Mast Cells Mitigates Peripheral and Central Inflammation After Stroke

Abstract

Stroke is the most common cause of long-term disability and places a high economic burden on the global healthcare system. Functional outcomes from stroke are largely determined by the extent of ischemic injury, however, there is growing recognition that systemic inflammatory responses also contribute to outcomes. Mast cells (MCs) rapidly respond to injury and release histamine (HA), a pro-inflammatory neurotransmitter that enhances inflammation. The gut serves as a major reservoir of HA. We hypothesized that cromolyn, a mast cell stabilizer that prevents the release of inflammatory mediators, would decrease peripheral and central inflammation, reduce MC trafficking to the brain, and improve stroke outcomes. We used the transient middle cerebral artery occlusion (MCAO) model of ischemic stroke in aged (18 mo) male mice to investigate the role of MC in neuroinflammation post-stroke. After MCAO we treated mice with 25 mg/kg body weight of cromolyn (MC stabilizer) by oral gavage. Cromolyn was administered at 3 h, 10 h, 24 h and every 24 h for 3 days post-stroke. Three control groups were used. One group underwent a sham surgery and was treated with cromolyn, one received sham surgery with PBS vehicle and the third underwent MCAO with PBS vehicle. Mice were euthanized at 24 h and 3 days post-stroke. Cromolyn administration significantly reduced MC numbers in the brain at both 24 h and 3 days post-stroke. Infarct volume was not significantly different between groups, however improved functional outcomes were seen at 3 days post-stroke in mice that received cromolyn. Treatment with cromolyn reduced plasma histamine and IL-6 levels in both the 24-h and 3-day cohorts. Gut MCs numbers were significantly reduced after cromolyn treatment at 24 h and 3 days after stroke. To determine if MC trafficking from the gut to the brain occurred after injury, GFPMCs were adoptively transferred to c-kit MC knock-out animals prior to MCAO. 24 h after stroke, elevated MC recruitment was seen in the ischemic brain. Preventing MC histamine release by cromolyn improved gut barrier integrity and an improvement in stroke-induced dysbiosis was seen with treatment. Our results show that preventing MC histamine release possesses prevents post-stroke neuroinflammation and improves neurological and functional outcomes.

Citing Articles

Research on the innate immune response in transgenic mice following ischemic stroke.

Yuan C, Shentu Y, Ji Q Front Aging Neurosci. 2024; 16:1476913.

PMID: 39649720 PMC: 11621074. DOI: 10.3389/fnagi.2024.1476913.


The Aging Immune System: A Critical Attack on Ischemic Stroke.

Xu W, Guo Y, Zhao L, Fu R, Qin X, Zhang Y Mol Neurobiol. 2024; 62(3):3322-3342.

PMID: 39271626 DOI: 10.1007/s12035-024-04464-2.


Role and mechanisms of mast cells in brain disorders.

Huang X, Lan Z, Hu Z Front Immunol. 2024; 15:1445867.

PMID: 39253085 PMC: 11381262. DOI: 10.3389/fimmu.2024.1445867.


CXCL6-CXCR2 axis-mediated PD-L2 mast cell accumulation shapes the immunosuppressive microenvironment in osteosarcoma.

Wang C, Lei Z, Zhang C, Hu X Heliyon. 2024; 10(14):e34290.

PMID: 39082021 PMC: 11284376. DOI: 10.1016/j.heliyon.2024.e34290.


Polymeric nanocarriers delivery systems in ischemic stroke for targeted therapeutic strategies.

Zhu L, Zhong W, Meng X, Yang X, Zhang W, Tian Y J Nanobiotechnology. 2024; 22(1):424.

PMID: 39026255 PMC: 11256638. DOI: 10.1186/s12951-024-02673-4.

References
1.
Kempuraj D, Selvakumar G, Thangavel R, Ahmed M, Zaheer S, Raikwar S . Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis. Front Neurosci. 2018; 11:703. PMC: 5733004. DOI: 10.3389/fnins.2017.00703. View

2.
McHale C, Mohammed Z, Deppen J, Gomez G . Interleukin-6 potentiates FcεRI-induced PGD biosynthesis and induces VEGF from human in situ-matured skin mast cells. Biochim Biophys Acta Gen Subj. 2018; 1862(5):1069-1078. PMC: 5866211. DOI: 10.1016/j.bbagen.2018.01.020. View

3.
Desai A, Jung M, Olivera A, Gilfillan A, Prussin C, Kirshenbaum A . IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J Allergy Clin Immunol. 2016; 137(6):1863-1871.e6. PMC: 4899186. DOI: 10.1016/j.jaci.2015.09.059. View

4.
Nechushtan H, Leitges M, Cohen C, Kay G, Razin E . Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cbeta. Blood. 2000; 95(5):1752-7. View

5.
Ganesh B, Fultz R, Ayyaswamy S, Versalovic J . Microbial interactions with the intestinal epithelium and beyond: Focusing on immune cell maturation and homeostasis. Curr Pathobiol Rep. 2018; 6(1):47-54. PMC: 6171525. DOI: 10.1007/s40139-018-0165-y. View